1 Supplementary Information

- 2 Peng et al.
- 3 Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies
- 4

that maintain potency against B.1.617

5 6





9 Supplementary Figure 1 | Measurement of mouse serum titers in SARS-CoV-2 Spike RBD immunized

10 mice in this study.

- a, Schematic of experiments. This schematic illustrates neutralizing antibody identification process through
 RBD-his tag protein mouse immunization-single B cell sequencing (Top), along with main assays of
 downstream analyses (Middle). The paired heavy chain and light chain sequences of the B cells were obtained
 using 10X Genomics VDJ sequencing. Antibodies were reconstructed by cloning of IgG heavy and light chains
 into human IgG1 backbone and expressed as recombinant monospecific or bispecific mAbs. Lead antibody
 clones were subjected to characterizations including neutralization assays, BL3 level anti- authentic SARS-
- 7 CoV-2 efficacy testing, and structural analyses by Cryo-EM. (Bottom) A timeline of mouse immunization for
- 8 antibody development.
- 9 b, SARS-CoV-2 RBD reactivity ELISA result of serum samples from different RBD immunized C57BL/6J
- 10 (b) (n=5 mice) and BALB/c (c) mice (n=3 mice).
- 11 c, SARS-CoV-2 RBD reactivity ELISA result of recombinant monospecific mAb clones identified from single
- 12 BCR sequencing of RBD immunized C57BL/6J (top) and BALB/c (bottom) mice. Data are presented as mean
- 13 values +/- SEM, n=3 biological replicates.
- 14 **d**, Schematics of construct design and antibody structure of bispecific antibodies used in this study.
- 15 e, SARS-CoV-2 RBD reactivity ELISA result of top monospecific mAb clones (Clones 2 and 6) and a
- 16 bispecific mAb clone (Clone 16). Data are presented as mean values +/- SEM, n=3 biological replicates.
- 17 Source data and additional statistics for experiments are provided in a supplemental excel file.





2 Supplementary Figure 2 | Neutralization capability testing of antibody clones with HIV1-based and

3 VSV-G-based WT SARS-CoV-2 spike pseudotyped virus.

- **a**, Schematics of initial mAb testing by neutralization assay and cell fusion assay.
- 5 b, Neutralization assay on Clone 2, Clone 6, Clone 5 and Clone 11 using WT SARS-CoV-2 Spike pseudotyped
- 6 VSV- virus carrying a luciferase reporter, n=3 biological replicates.
- 7 c, Neutralization assay on Clone 2, Clone 5, Clone 6, Clone 12 and Clone 13, using WT SARS-CoV-2 Spike
- 8 pseudotyped HIV-lentivirus carrying a luciferase reporter, n=3 biological replicates.
- 9 **d**, Cell fusion assay with SARS-CoV-2 Spike on top mAb clones, n=3 biological replicates.
- 10 e, Cell fusion assay with SARS-CoV-2 UK variant Spike on top mAb clones, n=3 biological replicates.
- 11 Source data and additional statistics for experiments are provided in a supplemental excel file.



Supplementary Figure 3 | Cryo-EM density maps of the ectodomain of SARS-CoV-2 S trimer (gray) in
 complexes with Clone 2 (a) or Clone 6 (b) Fabs (green, yellow and cyan).



2 Supplementary Figure 4 | Additional binding interfaces between spike RBD and both clone Fabs.

3 a, Overlay of a down-RBD-bound Clone 2 Fab (cyan ribbons with transparent surface) onto a down-RBD-

4 bound Clone 6 Fab (cyan surface) reveals a steric clash between the Clone 2 Fab and a neighboring RBD.

- 1 **b**, The additional binding interface between a down-RBD-binding Clone 2 Fab and an adjacent up-RBD in S
- 2 trimers with 2 RBDs up.
- 3 c, The down-RBD-binding Clone 6 Fab sits on top of two adjacent down-RBDs in S trimers with 2 or 3 RBDs
- 4 down. The CDRL1 loop highlighted in red inserts between two adjacent RBDs.
- 5 d, The additional binding interfaces between a down-RBD-binding Fab and adjacent down- or up-RBD in all
- 6 Clone 6 Fab-S trimer complexes. The residues involved in the interactions are highlighted in red.
- 7 e, ACE2 bound to an up-RBD has additional steric clashes with a neighboring down-RBD bound Clone 2 (left)
- 8 or Clone 6 (right) Fab in spike trimers with either 1 RBD up or 2 RBDs up. ACE2 is shown as light gray
- 9 surface, Clone 2 and 6 Fabs are shown as yellow (on down-RBD) or green (on up-RBD) ribbons, and RBDs
- 10 are shown as gray surfaces.
- 11



1 2

Supplementary Figure 5 | Detailed atomic interactions at the spike RBD-Fab interfaces.

a, Cryo-EM maps of the spike RBD binding interfaces with the Clone 2 Fab CDRH loops (upper panel) and
 CDRL loops (lower panel), with the fitted models in ribbon representation. The key interactions and

- 1 electrostatic surfaces (blue, positively charged; red, negatively charged) at the binding interfaces are shown in
- 2 respective insets.
- 3 **b,** Cryo-EM maps of the spike RBD binding interfaces with the Clone 6 Fab CDRH loops (upper panel) and
- 4 CDRL loops (lower panel), with the fitted models in ribbon representation. The key interactions are shown in
 5 respective insets.
- 6



Supplementary Figure 6 | Comparison of binding orientations between Clone 2/6 and previous reported antibodies on SARS-CoV-2 spike RBD, with the RBD portions overlaid. a, Three previously reported antibodies bind the spike RBD in overall similar orientations as those of Clone 2/6, but with substantial rotations or shifts. b, Two previous reported antibodies resemble the binding conformations of Clone 2/6 on

- 1 spike RBD, however with the positions of heavy chains and light chains swapped. The PDB IDs of the
- 2 published Fab-RBD structures: 2H2, 7DK5; CV05-163, 7LOP; S2H13, 7JV4; CT-P59, 7CM4; BD23, 7BYR.
- 3





Supplementary Figure 7 | Local resolution estimations of the cryo-EM maps of SARS-CoV-2 S

1 ectodomain trimer (gray) in complexes with Clone 2 (a) or Clone 6 (b) Fabs. Fourier shell correlation

2 (FSC) curves of the half-maps of each complex structure from gold standard refinement calculated by
 3 cryoSPARC are also shown, respectively.

4



5

Supplementary Figure 8 | Epitope and mutation analysis of the Fab-spike RBD interfaces for lead mAb clone in comparison with representative existing clinical antibodies

- 8 Structural comparison of Clone 2, REGN 10933 and REGN 10987 revealed their distinct RBD epitopes and
- 9 varied susceptibility to mutations of Delta variant. RBD structural model of Delta in complex with REGN
- 10 10987 (A, Pink, PDB: 6XDG), REGN 10933 (B, Pink, PDB: 6XDG) and Clone 2 (Cyan) is shown.
- 11 **a**, The epitope of REGN 10987 are mainly distributed in the left shoulder loop 1 (blue) region, which extends
- 12 to L452R mutation site, while the clone 2 mainly targets the right ridge of RBD.

- 1 b, The paratopes of REGN 10933 and clones targeting the E484Q of RBD are labeled and shown. The
- 2 remaining parts of the antibody structures were set 50% transparent.
- c, Overlay of structures of REGN 10933, RGEN 10987 and Clone 2 Fab with RBD, with analysis of
 representative key residues.

Clone 1-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGATATGCGGACACCCGCTCAATTTCTCGGGATTCTCCTCCTTTGGT TTCCTGGCATCAAATGCGATATTAAGATGACACAAAGTCCTTCTTCTATGTACGCCAGCCTCGGCGAACGGGTCACC ATAACTTGTAAGGCATCACAGGACATAAACTCATACCTTAGTTGGTTCCAACAGAAGCCAGGCAAAAGTCCTAAGA CTCTGATATATCGCGCTAATCGATTGGTGGGATGGGGTGCCCTCTCGCTTTTCCGGCAGTGGCTCCGGGCAAGACTAC TCTCTCACAATCAGCAGCTTGGAGTATGAAGACATGGGAATATACTACTGCCTCCAGTATGATGAAGACATTGGAG ATTTGGAGGCGGGACTAAATTGGAGATAAAGCGTACGGTGGCTGCACCATCTGTCTTCATC
Clone 2-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGAATCAGATACACTCCTCCTCTGGGTGCTTCTTTTGTGGGTGCCTG GGTCCACCGGGGACATTGTCCTTACCCAGTCACCCGCCTCCTTGGCAGTCAGT
Clone 3-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGTCTGTCCCCACACAAGTTCTCGGCCTGCTGCTCCTTTGGCTCACAG ATGCCCGGTGTGACATACAGATGACACAATCCCCCGCCAGTCTCTCAGCTTCCGTAGGGGAGACCGTAACCATTACC TGCCGAGCATCCGAGAATATTTACTCAAACTTGGCATGGTATCAGCAGAAGCAAGGAAAAAGCCCCCAACTCCTGG TTTACGTTGCCACAAATCTCGCCCACGGGGTCCCCTCAAGGTTCAGCGGTAGTGGCTCCGGGACCCAATACAGCCTG AAAATAAATAGCCTTCAGTCTGAGGATTTCGGGTCCTACTATTGCCAACATTTCTGGGGGACCCCAACCTTTGGAAG TGGGACCAAACTCGAAATCAAGCGTACGGTGGCTGCACCATCTGTCTTCATC
Clone 4-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGATGTCACCAGCTCAGTTCCTCTTCCTGTTGGTGCTCTGGATTCGAG AAACTAACGGAGATGTCGTGATGACCCAAACCCCACTTACTCTCTCCGTGACTATCGGCCAACCCGCTAGTATATCA TGTAAGTCATCTCAAAGTTTGTTGGATTCCGACGGCAGAGACATATCTTAATTGGCTGCTGCAACGCCCAGGACAGTC CCCTAAGAGACTGATCTATCTCGTGAGTAAGCTCGATAGCGGGGGTCCCTGACCGATTCACTGGTAGTGGAAGCGGTA CTGATTTTACCCTGAAGATTTCTCGGGGTCGAGGGCTGAGGGACCTCGGTGTATATTATTGTTGGCAGGGGAACTCACTTCC CATACACCTTCGGAGGCGGTACAAAGCTGGAAATAAAACGTACGGTGGCTGCACCATCTGTC
Clone 5-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGTGTTCACCCCCCACATCCTGGGCCTGCTGCTGTTCTGGATCAGCG CCAGCACCGGCGACATCCTGCTGACCCAGAGCCCCGCCACCCTGAGCGTGACCCCGGCGAGACCGTGAGCCTGAG CTGCAGGGCCAGCCAGAGCATCTACAAGAACCTGCACTGGTACCAGCAGAAGAGCCACAGGAGCCCCAGGCTGCTG ATCAAGTACGCCAGCGACAGCATCAGCGGCATCCCCAGCAGGTTCACCGGCAGCGGCAGCGGCACCGACTACACCC TGAGCATCAACAGCGTGAAGCCCGAGGGCATCCCCAGCAGGGCTACAGCGGCACCGGCACCGACTACACCC CGGCGCCGGCACCAAGCTGGAGCGAGGGCATCTACTACTGCCTGC
Clone 6-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGAGAAAGATACCCTCTTGCTCTGGGTACTGCTGCTCTGGGTGCCTG GGTCCACCGGCGACATTGTGCTGACACAATCACCTGCCTG
Clone 7-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGATGAGCCCCGCCCAGTTCCTGTTCCTGCTGGTGCTGTGGATCAGGG AGACCAACGGCGACGTGGTGATGACCCAGACCCCCTGACCCTGAGCGTGACCATCGGCCAGCCCGCCAGC CTGCAAGAGCAGCCAGAGCCTGCTGGACAGCGACGGCAAGACCTACCT

Clone 8-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGAAGCTGCCCGTGAGGCTGCTGGTGCTGATGTTCTGGATCCCCGCC AGCAGCAGCGACGTGCTGATGACCCAGACCCCCTGAGCCTGCCCGTGAGCCTGGGCGACCAGGCCAGCATCAGCT GCAGGAGCAGCCAGAGCATCGTGCACAGCAACGGCAACACCTACCT
Clone 9-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGATGAGCAGCGCCCAGTTCCTGGGCCTGCTGCTGCTGCTGCTTCCAG GGCACCAGGTGCGACCTGCAGATGACCCAGACCACCAGCAGCCGGAGCGCCAGCCTGGGGGGACAGGGTGACCATCA ACTGCAGGGCCAGCCAGGACATCACCAACTACCTGAACTGGTACCAGCAGAAGCCCGACGGCACCCTGAAGCTGCT GATCTACTACACCAGCAGGCTGCCCAGCGGCGTGCCCAGCAGGATCAGCGGCAGCGGCAGCGGCACCGACTACAGC CTGACCATCAGCAACCTGGAGCAGGAGGACATCGCCACCTACTTCTGCCAGCAGGGCAAGACCTTCCCCTGGACCTT CGGCGGCGGCACCAAGCTGGAGATCAAGAGGACGGTGGCTGCACCATCTGTCTTCATC
Clone 10-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGAGAGCCAGATCCAGGCCTTCGTGTTCGTGTTCCTGTGGCTGAGC GGCGTGGACGGCGACATCGTGATGACCCAGAGCCACAAGTTCATGAGCACCAGCGTGGGCGACAGGGTGAGCATCA CCTGCAAGGCCAGCCAGGACGTGAGCAGCGCCGTGGCCTGGTACCAGCAGAAGCCCGGCCAGAGCCCCAAGGTGCT GATCTACTGGGCCAGCACCAGGCACACCGGCGTGCCCGGACAGGTTCACCGGCAGCGGCAGCGGCACCGACTACAAC CTGACCATCAGGAGCGTGCAGGCCGAGGACCTGGCCCTGTACTACTGCCAGCAGCAGCAGCAGCACCAGGACCT CCGGCGGCGGCACCAAGCTGGAGATCAAGAGGACCGGTGGCTGCACCATCTGTCTTCATC
Clone 11-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGCGCCCATCTATACAGTTTTTGGGACTTCTTCTGTTCTGGCTTCATG GAGCACAATGCGATATACAAATGACCCAGTCCCCCTCCTCAGCGCCAGTTTGGGCGGCAAAGTCACTGTTACT TGCAAGGCCTCTCAGGACATAAACAAGTATATCGCTTGGTATCAACACAAGCCCGGTAAGGGACCACGGCTTCTGA TTCACTATACATCAACAACTTCAACCAGGGATTCCCCTCAAGATTCTCCGGCAGCGGTTCAGGGAGGG
Clone 12-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGAATCTGATACATTGCTTCTTTGGGTGCTCTTGCTGTGGGTTCCAG GCTCCACTGGAGATATTGTTATGACCCAAAGCCCTGATAGCCTCGCCGTCCCCTGGGCGAGCGGGGGGCGACGATTAAC TGCAGGGCATCAGAGAGTGTTGAATACTATGGTACAAGTCTCATGCAGTGGTATCAGCAAAAGCCCGGTCAGCCTC CGAAATTGTTGATATACGCAGCGTCCAACGTGGAATCCGGGGTGCCATCACGGTTCTCCGGTACGGGAGCGACGATACG GACTTCACCATTTCCTCTCTGCAGCCCGAGGATATTGCCACAATATTACTGTCAACAAAGTCGGAAAGTTCCA TGGACCTTCGGGGGTGGGACTAAAGTGGAGATAAAGCGAACGGTGGCTGCACCATCTGTCTTCATC
Clone 13-VK-gBlcok	CACTAAGTCTTGCACTTGTCACGAATTCAATGGAGTCCGATACCCTTCTCCTGTGGGTGCTGTTGCTTTGGGTCCCAG GCAGTACGGGAGATATTCAGATGACACAATCCCCCTCTAGCCTGTCAGCGTCCGTGGGCGACCGAGTTACGATTACC TGCCGAGCATCAGAATCCGTAGAGTATTATGGCACGTCTCTTATGCAATGGTATCAGCAGAAACCGGGTAAAGCGC CAAAACTGCTCATCTACGCGGCGTCTAACGTGGAGTCAGGTGTACCCTCCAGATTTTCTGGTTCAGGAAGCGGGGACT GATTTTACATTGACTATAAGCTCACTGCAACCGGAAGATTTCGCTACCTAC

South AfricangBlock1

UK varaint gBlock3

South AfricangBlock2

GTGTTCAATGCCACCAGGTTTGCCTCTGTCTATGCCTGGAACAGGAAGAGGATTAGCAACTGTGTGGCTGACTACTC CACCAATGTCTATGCTGACTCCTTTGTGATTAGGGGAGATGAGGTGAGACAGATTGCCCCTGGACAAACAGGCAAC ATTGCTGACTACAACTACAAACTGCCTGATGACTTCACAGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACAG CAAGGTGGGAGGCAACTACAACTACCTCTACAGACTGTTCAGGAAGAGCAACCTGAAACCATTTGAGAGGGACATC AGCACAGAGATTTACCAGGCTGGCAGCACCACCATGTAATGGAGTGAAGGGCTTCAACTGTTACTTTCCACTCCAATC ACTGACAGGCACAGGAGTGCTGACAGAGAGCAACAAGAAGTTCCTGCCATTCCAACAGTTTGGCAGGGACATTGCT GACACCACAGATGCTGTGAGGGACCCACAGACACTGGAGATTCTGGACATCACACCATGTTCCTTTGGAGGAGTGT CTGTGATTACACCTGGCACCAACACCAGCAACCAGGTGGCTGTGCTCTACCAGGATGTGAACTGTACTGAGGTGCCT GTGGCTATCCATGCTGACCAACCTTACACCAACCTGGAGGGTCTACAGCACAGGCAGCAATGTGTTCCAGACCAGGG CTGGCTGTCTGATTGGAGCAGAGCATGTGAACAACTCCTATGAGTGTGACATCCCAATTGGAGCAGGCATCTGTGCC TCCTACCAGACCCAGACCAACAGCCCAAGGAGGGCAAGGTCTGTGGCAAGCCAGAGCATCATTGCCTACACAATGA ACAGAGATTCTGCCTGTGAGTATGACCAAGACCTCTGTGGACTGTACAATGTATATCTGTGGAGACAGCACAG

del19R1

del19F1

cttaagcttggtaccgagctcggatccTCAACAACAGGAGCCACAGGAACAAC

GCTAGACTGGACAAGGTGGAGGC

pVP28gB4	AGAATGCCCAGGCTCTGAACACCCTGGTGAAGCAACTTTCCAGCAACTTTGGAGGCCATCTCCTCTGTGCTGAATGACATCCTGAGCAGACTGGA CAAGGTGGAGGCTGAGGTCCAGATTGACAGACTGATTACAGGCAGACTCCAATCCCTACAACCTATGTGACCCAACAACTTATCAGGGCTGCT GAGATTAGGGCATCTGCCAACCTGGCTGCCACCAAGATGAGTGAG
pVP28gB3	CCAACCTGGAGGGTCTACAGCACAGGCAGCAATGTGTTCCAGACCAGGGCTGGCT
pVP28gB2	GGCATCTACCAGACCAGCAACTTCAGGGTCCAACCAACAGAGAGCATTGTGAGGTTTCCAAACATCACCAACCTGTGTCCATTTGGAGAGGGTGT TCAATGCCACCAGGTTTGCCTCTGTCTATGCCTGGAACAGGAACAGGAATAGCAACTGTGTGGGCTGACTACTCTGTGCTCTACAACTCTGCCTCC TTCAGCACCTTCAAGTGTTATGGAGTGAGCCCAACCAAACTGAATGACCTGTGTTTCACCAATGTCTATGCTGACTACCATGTGTGATTAGGGGAGA TGAGGTGAGACAGATTGCCCCTGGACAAACAGGCAAGATTGCTGACTACAACTACAAACTGCCTGATGACTTCACAGGCTGTGTGATTGCCTG GAACAGCAACAACCTGGACAGCAAGGTGGGGAGGCAACTACAACTACAAGTACAAACTGCCTGATGACTTCACAGGCTGTGTGATTGCCTG GAACAGCAACAACCTGGACAGCAAGGTGGGGAGGCAACTACAACTACAAGTACAGGACTGTTCAGGAAGAGCAACCTGAAACCATTTGAGAGGG ACATCAGCACAGAGATTTACCAGGCTGGCAGCACCACCATGTAATGGAGTGCAGGGCTTCAACTGTTACTTTCCACTCCAATCCTATGGCTTCCAA CCAACCAATGGAGTGGGCTACCAACCATACAGGGTGGTGGTGCTGTCCTTTGAACTGCTCCATGCCCTGCCACAGTGTGTGGACCAAAGAAG AGCACCAACCTGGTGAAGAACAAGTGTGTGAACTTCAACTTCAATGGACTGACAGGCACAGGAGTGCTGACAGAGAGCAACAAGAAGTTCCT GCCATTCCAACAGTTTGGCAGGGACATTGCTGACACCACAGAGTGCTGTGGAGCCACAGGAGCTTCACGGGAGGAGTGCTGGACACAAGAAGTTCCT TTTGGAGGAGTGTCTGTGATTACACCTGGCACCCAACACCAGCAACCAGGCAGG
oVP28gB1	cactatagggagacccaagctggctagccaccATGTTTGTGTTCCTGGTGCTGCTGCCACTGGTGTCCAGCCAG

pVP28gB1